Ventus Therapeutics
Ventus Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small-molecule drugs for previously undruggable or poorly treated targets. Their pipeline includes VENT-02, a brain-penetrant NLRP3 inhibitor for Parkinson's disease, and VENT-03, a first-in-class cGAS inhibitor for lupus. The company leverages its proprietary ReSOLVE® platform, which combines AI/ML, protein science, structural biology, and biophysics to accelerate drug discovery. Ventus Therapeutics aims to address unmet needs in autoimmune and inflammatory diseases, neurological disorders, and cancer.
Ventus Therapeutics
Ventus Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small-molecule drugs for previously undruggable or poorly treated targets. Their pipeline includes VENT-02, a brain-penetrant NLRP3 inhibitor for Parkinson's disease, and VENT-03, a first-in-class cGAS inhibitor for lupus. The company leverages its proprietary ReSOLVE® platform, which combines AI/ML, protein science, structural biology, and biophysics to accelerate drug discovery. Ventus Therapeutics aims to address unmet needs in autoimmune and inflammatory diseases, neurological disorders, and cancer.
TL;DR
Stage: Clinical-stage
Founded: 2020
Lead programs: VENT-02 (NLRP3, Phase 2), VENT-03 (cGAS, Phase 2)
Platform: ReSOLVE (structure + AI/ML)
Reported total funding: Approximately $290M–$370M (multiple disclosed rounds)
Company Overview
Problem Domain
Autoimmune and inflammatory diseases, neurological disorders, oncology (small-molecule discovery against innate immune targets).
Founded
2020
Industry
Biopharmaceuticals
Tech Stack
Funding Track Record
100000000.00
Reported $100M Series B led by RA Capital with participation from other healthcare investors.
140000000.00
Series C financing announced Feb 9, 2022.
Peripherally-restricted NLRP3 program (VENT-01) was exclusively licensed to Novo Nordisk.
Grant awarded to support Parkinson's-related research/program.
Investor Signal
“Participation from top-tier healthcare investors including SoftBank Vision Fund 2, RA Capital Management, Versant Ventures, GV, and others”